Surgery Websites
Colorectal Surgery »  Faculty »  Medical Oncology »  R. Kate Kelley, M.D.
R. Kate Kelley, M.D.

R. Kate Kelley, M.D.

  • Health Sciences Professor of Clinical Medicine,
  • Division of Hematology Oncology
  • Department of Medicine

Contact Information

(415) 353-9888 (appts)
(415) 353-9959 (fax)
1600 Divisadero St.,MZ Bldg A 
San Francisco, CA 94143-1770
Open Popup
Dr. Robin Kate Kelley is a gastrointestinal oncologist who specializes in cancers arising from the liver, including hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), and gallbladder carcinoma. Her research interests include developing clinical trials of new treatments and combination therapies for these cancers, including immunotherapy approaches as well as translational research to identify molecular and genetic biomarkers of response. Dr. Kelley graduated from the David Geffen School of Medicine at UCLA and completed a residency at UCLA, where she was chief resident in internal medicine. She then completed a fellowship in hematology and oncology at UCSF.

Dr. Kelley received an American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Merit Award in 2009, an ASCO Young Investigator Award in 2010, and the National Cancer Institute Cancer Clinical Investigator Team Leadership Award in 2014. She has authored numerous publications about treatments for advanced liver and bile duct cancers. She is involved in many organizations dedicated to improving the outcomes for patients with primary liver cancers, including National Comprehensive Cancer Network (NCCN) guideline panel for Liver Cancers, the National Cancer Institute Hepatobiliary Cancer Task Force, the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board, and the International Liver Cancer Association Education Committee.
  Dept or School    
  End Date    
  • University of California San Francisco, San Francisco, CA
  • Fellowship
  • Hematology/Oncology
  • 10/2009
  • University of California Los Angeles, Los Angeles, CA
  • M.D.
  • School of Medicine
  • 05/2002
  • Harvard College, Boston, MA
  • A.B.
  • Biochemical Sciences
  • 05/1997
  • University of California Los Angeles, Los Angeles, CA
  • Chief Residency
  • Internal Medicine
  • 06/2006
  • University of California Los Angeles, Los Angeles, CA
  • Residency
  • Internal Medicine
  • 05/2005
    • UCLA, Intern, 2002-05, Medicine
    • UCLA, Resident, 2005-06, Medicine
    • UCSF, Fellow, 2006-09, Hematology/Oncology
    • American Board of Internal Medicine
    • American Board of Internal Medicine: Medical Oncology - Subspecialty
    • UCSF Helen Diller Family Comprehensive Cancer Center
    • Anal Cancer
    • Colorectal Cancer
    • Hepatocellular Carcinoma (Liver Cancer)
    • Liver Metastases
    • Molecular Markers in Solid Tumors
    • Rectal Cancer
    Data provided by UCSF Profiles, powered by CTSI
    1. Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Kl?mpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A, KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Apr 14. View in PubMed
    2. Munson PV, Adamik J, Hartmann FJ, Favaro PMB, Ho D, Bendall SC, Combes AJ, Krummel MF, Zhang K, Kelley RK, Butterfield LH. Polyunsaturated fatty acid-bound alpha-fetoprotein promotes immune suppression by altering human dendritic cell metabolism. Cancer Res. 2023 Feb 27. View in PubMed
    3. Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, Kelley RK, Wang XW. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2023 Jan 25. View in PubMed
    4. Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA, FOENIX-CCA2 Study Investigators. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023 Jan 19; 388(3):228-239. View in PubMed
    5. Song X, Kelley RK, Khan AA, Standifer N, Zhou D, Lim K, Krishna R, Liu L, Wang K, McCoon P, Negro A, He P, Gibbs M, Kurland JF, Abou-Alfa GK. Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma. Clin Cancer Res. 2023 02 16; 29(4):754-763. View in PubMed
    6. View All Publications


    Site Directory